InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 28 March 2024

MarkV-01: This study is evaluating how safe, tolerable and effective a new targeted therapy is when given alone, or in combination with immunotherapy, in people with advanced or metastatic solid cancersA Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors

Clinical summary

Summary

Phase 1a of this study is planned as a dose escalation of the study drug (called PMC-309) when given alone or in combination with immunotherapy (called pembrolizumab). Both PMC-309 and pembrolizumab will be given intravenously. 

  • Part A is planned as a dose escalation of the study drug (called PMC-309) given alone.
  • Part B is planned as a PMC-309 dose escalation in combination with immunotherapy (called pembrolizumab).

Part B will establish the maximum tolerated dose (MTD)/preliminary recommended phase 2 dose (RP2D) of PMC-309 when given in combination with 200mg pembrolizumab. Part B will be conducted after completion of Part A and before the commencement of Phase 1b.

Phase 1b of this study is planned as a cohort expansion to further evaluate the study PMC-309 when given alone or in combination withpembrolizumab. 

 

 

Conditions

This trial is treating patients with advanced or metastatic solid cancers

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

I

Trial Acronym

MarkV-01

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

PharmAbcine

Scientific Title

A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors

Eligibility

Inclusion

To be eligible for this study, a participant must meet ALL of the following inclusion criteria:

  1. The participant voluntarily signs an informed consent form (ICF) indicating they understand the purpose and procedures required for the study and are willing to participate in the study.
  2. Are at least 18 years of age.
  3. Are diagnosed with advanced or metastatic solid tumors (non-lymphoma) by histology or pathology that is metastatic or unresectable and considered relapsed and/or refractory to prior therapy.

    Definition of anti-PD-1/L1 refractory participant:

    Participants must have progressed on treatment with an anti-PD1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:

    1. Has received at least 2 doses of an approved anti-PD-1/L1 mAb.
    2. Has demonstrated disease progression (PD) after PD-1/L1 as defined by RECIST v1.1. The initial evidence of PD is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented PD, in the absence of rapid clinical progression.
    3. PD has been documented within 12 weeks from the last dose of anti-PD-1/L1 mAb.

    i. PD is determined according to iRECIST v1.1. ii. This determination is made by the PI (or designee). Once PD is confirmed, the initial date of PD documentation will be considered the date of disease progression

  4. Have measurable disease per RECIST v1.1 documented by computerized tomography scan (CT scan) and/or magnetic resonance imaging (MRI), measurable at Baseline. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  5. Have an ECOG performance status of 0 or 1.
  6. Can satisfy the following criteria in hematologic, renal, and hepatic function tests performed within 7 days prior to screening:

    1. Hematologic tests:

      • ANC more than and equal to 1.5 × 109 per L.
      • Platelets more than and equal to 100 × 109 per L.
      • Hemoglobin more than and equal to 9.0 g per dL or more than and equal to 5.6 mmol per L.

      Note: Criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Participants can be on a stable dose of erythropoietin (more than equal to approximately 3 months).

    2. Blood coagulation tests:

      • Prothrombin time less than and equal to 1.5 × upper limit of normal (ULN).
      • Activated partial thromboplastin time less than and equal to 1.5 × ULN.
    3. Hepatic function tests:

      • Total bilirubin less than and equal to 1.5 × ULN or direct bilirubin less than and equal to ULN for participants with total bilirubin levels more than and equal to 1.5 × ULN.
      • Aspartate aminotransferase or alanine aminotransferase less than and equal to 2.5 × ULN (less than and equal to 5× ULN in case of liver metastasis).
    4. Renal function test:

      • less than and equal to 1.5 × ULN or creatinine clearance more than and equal to 30 mL/min for participant with creatinine levels above 1.5 × institutional ULN.
  7. Are willing and able to adhere to the prohibitions and restrictions as specified in the study protocol.
  8. Eligible participants (male and female) of childbearing potential must agree to use reliable contraception (hormone, barrier method, or abstinence) from Screening (Day -1) until at least 120 days after administration of the last dose of the IP.
  9. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at Screening (Day -1) and be willing to have additional pregnancy tests as required throughout the study.
  10. Human immunodeficiency virus (HIV) infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:

    1. Participants on ART must have a CD4+ T-cell count 350 cells/mm3 at time of Screening.
    2. Participants on ART must have achieved and maintained virologic suppression defined as confirmed by HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of Screening and for at least 12 weeks prior to Screening.
    3. Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).

Exclusion

A participant who meets ANY of the following exclusion criteria must be excluded from the study:

  1. Has received treatment with a VISTA targeting agent.
  2. Has a history of positive testing for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-hepatitis C virus) or other clinically active liver disease, or positive testing at Screening for HBsAg or anti- hepatitis C virus.
  3. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  4. Has a medical condition which, in the opinion of the PI (or designee), places the participant at an unacceptably high risk for toxicity.
  5. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
  6. Is currently participating in or has participated in a study of an investigational agent or have received anticancer immunotherapy within 4 weeks prior to the first dose of IP.
  7. Has an active autoimmune disease with a history of flares requiring immunosuppressant medications within the past 6 months or that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
  8. History of known or suspected seizure disorder.
  9. Has oxygen-dependent chronic disease.
  10. Serious Grade 4 venous thromboembolic event including pulmonary embolism.
  11. Participant is receiving therapeutic anticoagulants.
  12. Has had an allogeneic tissue/solid organ transplant.
  13. Major surgery (eg, requiring general anesthesia) within 4 weeks before the planned first dose of the IP, or not fully recovered from prior surgery, or has surgery planned during the time the participant is expected to participate in the study or within 4 weeks after the last dose of IP.
  14. Fertility exclusions:

    1. Participant is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 120 days after the last dose of IP; WOCBP must have a negative pregnancy status confirmed by urine pregnancy test at Screening and within 72 hours of first dose of the IP. (If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.)
    2. Participant is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of the IP.
    3. Male participants must also refrain from sperm donation during the treatment period and for 5 terminal half-lives (of PMC-309) plus an additional 90 days (a spermatogenesis cycle).

    Note: The half-life of PMC-309 is 47 hours.

  15. Vaccinated with a live vaccine within 30 days (with the exception of the annual inactivated influenza vaccine) prior to the first dose of the IP.
  16. Received COVID-19 vaccine within 7 days of the first IP administration.
  17. Any medical condition for which, in the opinion of the PI or designee, participation would not be in the best interest of the participant (eg, compromise the well-being of the participant) or that could prevent, limit, or confound the protocol specified assessments.
  18. Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension; poorly controlled diabetes; ongoing active infection requiring antibiotics or acute infectious illness (including suspected viral infection); symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia considered to increase risk for the participant by the PI (or designee); or active psychiatric disorder (schizophrenia, major depressive disorder, bipolar disorder, treated depression with ongoing antidepressant medication etc.) that would limit compliance with study requirements.
  19. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (at a dose exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of IP.
  20. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, (ie, without evidence of progression for at least 4 weeks by repeat imaging [note that the repeat imaging should be performed during Screening], clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of IP).
  21. Prior allogeneic organ or bone marrow transplant.
  22. Participant has had prior therapy meeting the following:

    1. Prior T-cell receptor-modified or chimeric antigen receptor T-cell (CART) therapy.
    2. Other anticancer therapy, including chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 4 weeks prior to the first dose of IP.
    3. Has received prior radiotherapy (excluding limited palliative radiation) within 2 weeks of start of IP or has a history of radiation pneumonitis.
    4. Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation (less than and equal to 2 weeks of radiotherapy) to non-CNS disease.
    5. Except for hearing loss, alopecia and pigmentation, all toxicity caused by previous anti-tumor therapy has recovered to Grade 1 or less.
  23. Participant received prior therapy with an anti-PD-1 or anti-PD-L1 mAb or with an agent targeting stimulatory or co-inhibitory T-cell receptors and was discontinued from that treatment due to a Grade 3 or higher immune related AE.
  24. Participant has an active autoimmune disease that required systemic treatment in the past.
  25. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  26. Class III or IV heart failure by New York Heart Association (NYHA) classification.
  27. History of abdominal fistula or gastrointestinal perforation within 6 months prior to start of IP administration.
  28. History of serious gastrointestinal hemorrhage within 6 months prior to start of IP administration.
  29. History of hypertensive crisis or hypertensive encephalopathy.
  30. History of posterior reversible encephalopathy syndrome.
  31. Social situation that would limit compliance with study requirements.
  32. A diagnosis of immunodeficiency or is receiving chronic systemic corticosteroids at a dose that exceeds 10 mg daily of prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior the first dose of the IP. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.

Inclusion

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.